MacroGenics, Inc. (MGNX) Investor Relations Documents

MacroGenics, Inc. (MGNX) investor relations documents from the company's IR site: 4 presentations, 36 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Corporate Presentation - August 2026: Corporate update on novel platform technologies and pipeline, including MGC026 (B7-H3 ADC) and Lorigerlimab (PD-1 x CTLA-4), with cash runway through 2028.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13PresentationCorporate Presentation - August 2026
2026-08-13Press releaseMacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Positi
2026-08-11Press releaseMacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical
2026-07-23PresentationCorporate Presentation - July 2026
2026-07-23Press releaseMacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
2026-07-02Press releaseMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-06-22Press releaseMacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-05-14Press releaseMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
2026-05-13Press releaseMacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
2026-05-11Press releaseMacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
2026-05-04Press releaseMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
2026-04-08Press releaseFDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
2026-03-09Press releaseMacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
2026-02-26Press releaseMacroGenics to Participate in Upcoming Investor Conferences
2026-02-23Press releaseMacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
Press releaseMacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
Press releaseMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
Press releaseMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
Press releaseMacroGenics Announces Date of First Quarter 2025 Financial Results
2025-03-20Press releaseMacroGenics Provides Update on Corporate Progress and 2024 Financial Results
2025-03-06Press releaseMacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
2024-11-06Press releaseMacroGenics to Participate in Upcoming Investor Conferences
2024-10-30Press releaseMacroGenics Announces Leadership Transition
2024-09-16PresentationPost-ESMO Conference Presentation
2024-09-08Press releaseMacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
2024-05-13Press releaseMacroGenics to Participate in Upcoming Investor Conferences
2024-05-09Earnings deckTAMARACK Phase 2 Interim Data (April 12, 2024 data cut-off)
2024-05-09Press releaseMacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Stu
2024-04-03Press releaseMacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
2024-03-01Press releaseMacroGenics to Participate in Upcoming Investor Conferences
2024-01-08Press releaseMacroGenics to Participate in Upcoming Investor Conference
2023-10-31Press releaseMacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
2023-08-09Press releaseMacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
2023-07-31Press releaseMacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
2023-05-09Press releaseMacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
2023-05-04Press releaseMacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
2023-03-15Press releaseMacroGenics Provides Corporate Update and 2022 Financial Results
2023-03-07Press releaseMacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
2022-11-03Press releaseMacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
2022-10-26Press releaseMacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

MGNX overview · MGNX earnings · MGNX financials · MGNX KPIs · MGNX ownership · MGNX peers · MGNX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.